



Reference: FOI.ICB-2526/006

Subject: ICB Formulary; Diabetes (CGM & BGM)

I can confirm that the ICB does hold the information requested; please see responses below:

QUESTION	RESPONSE	
I am requesting the following information in respect of:		
Diabetes: - SMBG test strips - CGM - Continuous Glucose monitoring systems		
 The name(s) and direct contact email address(es) and direct telephone numbers of the person(s) who are responsible for the formulary The date of the next review of your formulary Details of how you intend to review your formulary (include process, timelines) Details if part of a local partnership arrangement for formulary review. Please provide the contact's name, email address and telephone number for the person with 	 For both SMBG and CGM the contact for responsibility for the formulary are the BNSSG Formulary Team - bnssg.formulary@nhs.net Both BNSSG guidelines for SMBG are due for review in April 2027 BNSSG Type 1 Blood Glucose Monitoring Guidance (Primary Care) BNSSG Type 2 Diabetes Blood Glucose Monitoring Guidance (Adults) 	
responsibility where a partnership arrangement is in place.	The <u>Clinical Pathway for the use of diabetes technologies in</u> <u>all patients with Type 1 Diabetes</u> is currently under review.	





The Clinical Pathway for the use of diabetes technologies in all patients with Type 2 Diabetes is due for review in November 2026. 3. Please see Formulary Process (Remedy BNSSG ICB) for details of Formulary process including the Terms of
Reference for the group. 4. N/A

The information provided in this response is accurate as of 24 April 2025 and has been approved for release by Dr Joanne Medhurst, Chief Medical Officer for NHS Bristol, North Somerset and South Gloucestershire ICB.